{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:10:47Z","timestamp":1780967447746,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.7759\/cureus.81573","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T20:14:09Z","timestamp":1743538449000},"source":"Crossref","is-referenced-by-count":4,"title":["Emerging Therapeutic Strategies for Heart Failure: A Comprehensive Review of Novel Pharmacological and Molecular Targets"],"prefix":"10.7759","author":[{"given":"Elizabeth Caroline","family":"Palaparthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Padala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reva","family":"Singamaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachakatla","family":"Manaswini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigna","family":"Kantula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Aditya Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punuri","family":"Chandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addanki","family":"Sathwika Eliana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papasani","family":"Siri Samhita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth Kumar","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00646-4","article-title":"Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits","volume":"24","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Wang C, Tu T, et al.. Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits. Am J Cardiovasc Drugs. 2024, 24:329-42. 10.1007\/s40256-024-00646-4","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger RH","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021, 11:263-76. 10.21037\/cdt-20-302","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015472","article-title":"Neurohumoral activation in heart failure","volume":"24","author":"Manolis AA","year":"2023","unstructured":"Manolis AA, Manolis TA, Manolis AS. Neurohumoral activation in heart failure. Int J Mol Sci. 2023, 24:15472. 10.3390\/ijms242015472","journal-title":"Int J Mol Sci"},{"key":"ref5","article-title":"SGLT2 inhibitors in heart failure with reduced ejection fraction","volume":"73","author":"Das US","year":"2021","unstructured":"Das US, Paul A, Banerjee S. SGLT2 inhibitors in heart failure with reduced ejection fraction. Egypt. Heart J. 2021, 73:1-7.","journal-title":"Egypt. Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/10742484211042706","article-title":"The role of sGC stimulators and activators in heart failure with reduced ejection fraction","volume":"26","author":"Cordwin DJ","year":"2021","unstructured":"Cordwin DJ, Berei TJ, Pogue KT. The role of sGC stimulators and activators in heart failure with reduced ejection fraction. J Cardiovasc Pharmacol Ther. 2021, 26:593-600. 10.1177\/10742484211042706","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_39_21","article-title":"Cardiac myosin activation in the treatment of congestive heart failure: new therapeutic options and review of literature","volume":"22","author":"Ali A","year":"2021","unstructured":"Ali A, Abdelmaseih R, Thakker R, Faluk M, Hasan SM. Cardiac myosin activation in the treatment of congestive heart failure: new therapeutic options and review of literature. Heart Views. 2021, 22:275-9. 10.4103\/HEARTVIEWS.HEARTVIEWS_39_21","journal-title":"Heart Views"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302970","article-title":"Molecular targets of current and prospective heart failure therapies","volume":"99","author":"Chemaly ER","year":"2013","unstructured":"Chemaly ER, Hajjar RJ, Lipskaia L. Molecular targets of current and prospective heart failure therapies. Heart. 2013, 99:992-1003. 10.1136\/heartjnl-2012-302970","journal-title":"Heart"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.34172\/jcvtr.2022.14","article-title":"A glance at the application of CRISPR\/Cas9 gene-editing technology in cardiovascular diseases","volume":"14","author":"Roshanravan N","year":"2022","unstructured":"Roshanravan N, Tutunchi H, Najafipour F, Dastouri M, Ghaffari S, Jebeli A. A glance at the application of CRISPR\/Cas9 gene-editing technology in cardiovascular diseases. J Cardiovasc Thorac Res. 2022, 14:77-83. 10.34172\/jcvtr.2022.14","journal-title":"J Cardiovasc Thorac Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.02.003","article-title":"Utilization and potential of RNA-based therapies in cardiovascular disease","volume":"7","author":"Robinson EL","year":"2022","unstructured":"Robinson EL, Port JD. Utilization and potential of RNA-based therapies in cardiovascular disease. JACC Basic Transl Sci. 2022, 7:956-69. 10.1016\/j.jacbts.2022.02.003","journal-title":"JACC Basic Transl Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2010.11.011","article-title":"Cardiac gene therapy with SERCA2a: from bench to bedside","volume":"50","author":"Gwathmey JK","year":"2011","unstructured":"Gwathmey JK, Yerevanian AI, Hajjar RJ. Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol. 2011, 50:803-12. 10.1016\/j.yjmcc.2010.11.011","journal-title":"J Mol Cell Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2020.08.005","article-title":"Extracellular vesicles in cardiac regeneration: potential applications for tissues-on-a-chip","volume":"39","author":"Wagner KT","year":"2021","unstructured":"Wagner KT, Nash TR, Liu B, Vunjak-Novakovic G, Radisic M. Extracellular vesicles in cardiac regeneration: potential applications for tissues-on-a-chip. Trends Biotechnol. 2021, 39:755-73. 10.1016\/j.tibtech.2020.08.005","journal-title":"Trends Biotechnol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/term.2954","article-title":"Cardiac regeneration using human-induced pluripotent stem cell-derived biomaterial-free 3D-bioprinted cardiac patch in vivo","volume":"13","author":"Yeung E","year":"2019","unstructured":"Yeung E, Fukunishi T, Bai Y, et al.. Cardiac regeneration using human-induced pluripotent stem cell-derived biomaterial-free 3D-bioprinted cardiac patch in vivo. J Tissue Eng Regen Med. 2019, 13:2031-9. 10.1002\/term.2954","journal-title":"J Tissue Eng Regen Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2023.0050","article-title":"Application and potential of artificial intelligence in heart failure: past, present, and future","volume":"6","author":"Yoon M","year":"2024","unstructured":"Yoon M, Park JJ, Hur T, Hua CH, Hussain M, Lee S, Choi DJ. Application and potential of artificial intelligence in heart failure: past, present, and future. Int J Heart Fail. 2024, 6:11-19. 10.36628\/ijhf.2023.0050","journal-title":"Int J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.01.001","article-title":"Heart failure with preserved ejection fraction: classification based upon phenotype is essential for diagnosis and treatment","volume":"28","author":"Xanthopoulos A","year":"2018","unstructured":"Xanthopoulos A, Triposkiadis F, Starling RC. Heart failure with preserved ejection fraction: classification based upon phenotype is essential for diagnosis and treatment. Trends Cardiovasc Med. 2018, 28:392-400. 10.1016\/j.tcm.2018.01.001","journal-title":"Trends Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2022.11.1.1","article-title":"SGLT2 inhibitors and ketone metabolism in heart failure","volume":"11","author":"Saucedo-Orozco H","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler. 2022, 11:1-19. 10.12997\/jla.2022.11.1.1","journal-title":"J Lipid Atheroscler"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz916","article-title":"The dapagliflozin and prevention of adverse outcomes in Heart Failure Trial (DAPA-HF) in context","volume":"42","author":"McMurray JJ","year":"2021","unstructured":"McMurray JJ, Solomon SD, Docherty KF, Jhund PS. The dapagliflozin and prevention of adverse outcomes in Heart Failure Trial (DAPA-HF) in context. Eur Heart J. 2021, 42:1199-202. 10.1093\/eurheartj\/ehz916","journal-title":"Eur Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial","volume":"77","author":"Packer M","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al.. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol. 2021, 77:1381-92. 10.1016\/j.jacc.2021.01.033","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000929","article-title":"Cardiac myosin activation for the treatment of systolic heart failure","volume":"77","author":"Bernier TD","year":"2021","unstructured":"Bernier TD, Buckley LF. Cardiac myosin activation for the treatment of systolic heart failure. J Cardiovasc Pharmacol. 2021, 77:4-10. 10.1097\/FJC.0000000000000929","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang C","year":"2021","unstructured":"Chuang C, Collibee S, Ashcraft L, et al.. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021, 64:14142-52. 10.1021\/acs.jmedchem.1c01290","journal-title":"J Med Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17781","article-title":"Soluble guanylate cyclase stimulators in heart failure","volume":"13","author":"Kansakar S","year":"2021","unstructured":"Kansakar S, Guragain A, Verma D, et al.. Soluble guanylate cyclase stimulators in heart failure. Cureus. 2021, 13:e17781. 10.7759\/cureus.17781","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2720","article-title":"Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum","volume":"24","author":"Butler J","year":"2022","unstructured":"Butler J, Usman MS, Anstrom KJ, et al.. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022, 24:2029-36. 10.1002\/ejhf.2720","journal-title":"Eur J Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20230670","article-title":"Diastolic strain parameters are associated with short term mortality and rehospitalization in patients with advanced heart failure","volume":"121","author":"Tatar S","year":"2024","unstructured":"Tatar S, \u0130cli A, Ar\u0131ba\u015f A, Akilli NB, Akilli H, Sertdemir AL. Diastolic strain parameters are associated with short term mortality and rehospitalization in patients with advanced heart failure. Arq Bras Cardiol. 2024, 121:e20230670. 10.36660\/abc.20230670","journal-title":"Arq Bras Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2017.12.006","article-title":"Gene editing and gene-based therapeutics for cardiomyopathies","volume":"14","author":"Ohiri JC","year":"2018","unstructured":"Ohiri JC, McNally EM. Gene editing and gene-based therapeutics for cardiomyopathies. Heart Fail Clin. 2018, 14:179-88. 10.1016\/j.hfc.2017.12.006","journal-title":"Heart Fail Clin"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac463","article-title":"Small non-coding RNA therapeutics for cardiovascular disease","volume":"43","author":"Shah AM","year":"2022","unstructured":"Shah AM, Giacca M. Small non-coding RNA therapeutics for cardiovascular disease. Eur Heart J. 2022, 43:4548-61. 10.1093\/eurheartj\/ehac463","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel J","year":"2021","unstructured":"T\u00e4ubel J, Hauke W, Rump S, et al.. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021, 42:178-88. 10.1093\/eurheartj\/ehaa898","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai S","year":"2021","unstructured":"Batkai S, Genschel C, Viereck J, et al.. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021, 42:192-201. 10.1093\/eurheartj\/ehaa791","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010051","article-title":"Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction","volume":"16","author":"Mooney L","year":"2023","unstructured":"Mooney L, Jackson CE, Adamson C, et al.. Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circ Heart Fail. 2023, 16:e010051. 10.1161\/CIRCHEARTFAILURE.122.010051","journal-title":"Circ Heart Fail"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01845-6","article-title":"Inflammation in heart failure: pathophysiology and therapeutic strategies","volume":"73","author":"Boulet J","year":"2024","unstructured":"Boulet J, Sridhar VS, Bouabdallaoui N, Tardif JC, White M. Inflammation in heart failure: pathophysiology and therapeutic strategies. Inflamm Res. 2024, 73:709-23. 10.1007\/s00011-023-01845-6","journal-title":"Inflamm Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112584","article-title":"Regenerative strategies for the consequences of myocardial infarction: chronological indication and upcoming visions","volume":"146","author":"Tajabadi M","year":"2022","unstructured":"Tajabadi M, Goran Orimi H, Ramzgouyan MR, Nemati A, Deravi N, Beheshtizadeh N, Azami M. Regenerative strategies for the consequences of myocardial infarction: chronological indication and upcoming visions. Biomed Pharmacother. 2022, 146:112584. 10.1016\/j.biopha.2021.112584","journal-title":"Biomed Pharmacother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2024.11.005","article-title":"Extracellular vesicle therapeutics for cardiac repair","volume":"199","author":"Hu Y","year":"2025","unstructured":"Hu Y, Zhang W, Ali SR, et al.. Extracellular vesicle therapeutics for cardiac repair. J Mol Cell Cardiol. 2025, 199:12-32. 10.1016\/j.yjmcc.2024.11.005","journal-title":"J Mol Cell Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7150\/thno.61621","article-title":"3D bioprinting in cardiac tissue engineering","volume":"11","author":"Wang Z","year":"2021","unstructured":"Wang Z, Wang L, Li T, Liu S, Guo B, Huang W, Wu Y. 3D bioprinting in cardiac tissue engineering. Theranostics. 2021, 11:7948-69. 10.7150\/thno.61621","journal-title":"Theranostics"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020987","article-title":"Induced pluripotent stem cell-derived cardiomyocytes therapy for ischemic heart disease in animal model: a meta-analysis","volume":"25","author":"Vo QD","year":"2024","unstructured":"Vo QD, Saito Y, Nakamura K, Iida T, Yuasa S. Induced pluripotent stem cell-derived cardiomyocytes therapy for ischemic heart disease in animal model: a meta-analysis. Int J Mol Sci. 2024, 25:1-19. 10.3390\/ijms25020987","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102660","article-title":"Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review","volume":"73","author":"Singh M","year":"2024","unstructured":"Singh M, Kumar A, Khanna NN, et al.. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review. EClinicalMedicine. 2024, 73:102660. 10.1016\/j.eclinm.2024.102660","journal-title":"EClinicalMedicine"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59661","article-title":"Artificial intelligence and its role in diagnosing heart failure: a narrative review","volume":"16","author":"Medhi D","year":"2024","unstructured":"Medhi D, Kamidi SR, Mamatha Sree KP, Shaikh S, Rasheed S, Thengu Murichathil AH, Nazir Z. Artificial intelligence and its role in diagnosing heart failure: a narrative review. Cureus. 2024, 16:e59661. 10.7759\/cureus.59661","journal-title":"Cureus"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-017-9756-y","article-title":"Precision medicine for heart failure with preserved ejection fraction: an overview","volume":"10","author":"Shah SJ","year":"2017","unstructured":"Shah SJ. Precision medicine for heart failure with preserved ejection fraction: an overview. J Cardiovasc Transl Res. 2017, 10:233-44. 10.1007\/s12265-017-9756-y","journal-title":"J Cardiovasc Transl Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15205","article-title":"State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age","author":"Rasalam R","year":"2025","unstructured":"Rasalam R, Sindone A, Deed G, Audehm RG, Atherton JJ. State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age. ESC Heart Fail. 2025, 1-14. 10.1002\/ehf2.15205","journal-title":"ESC Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2023.0058","article-title":"Precision cardiology: phenotype-targeted therapies for HFmrEF and HFpEF","volume":"6","author":"Rosano GM","year":"2024","unstructured":"Rosano GM, Vitale C, Spoletini I. Precision cardiology: phenotype-targeted therapies for HFmrEF and HFpEF. Int J Heart Fail. 2024, 6:47-55. 10.36628\/ijhf.2023.0058","journal-title":"Int J Heart Fail"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46486","article-title":"Advancements in heart failure management: a comprehensive narrative review of emerging therapies","volume":"15","author":"Sapna F","year":"2023","unstructured":"Sapna F, Raveena F, Chandio M, et al.. Advancements in heart failure management: a comprehensive narrative review of emerging therapies. Cureus. 2023, 15:e46486. 10.7759\/cureus.46486","journal-title":"Cureus"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12226956","article-title":"New challenges in heart failure with reduced ejection fraction: managing worsening events","volume":"12","author":"Lavalle C","year":"2023","unstructured":"Lavalle C, Di Lullo L, Jabbour JP, et al.. New challenges in heart failure with reduced ejection fraction: managing worsening events. J Clin Med. 2023, 12:2-14. 10.3390\/jcm12226956","journal-title":"J Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2018.10.002","article-title":"Managing the economic challenges in the treatment of heart failure","volume":"61","author":"Pi\u00f1a IL","year":"2018","unstructured":"Pi\u00f1a IL, Desai NR, Allen LA, Heidenreich P. Managing the economic challenges in the treatment of heart failure. Prog Cardiovasc Dis. 2018, 61:476-83. 10.1016\/j.pcad.2018.10.002","journal-title":"Prog Cardiovasc Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010227","article-title":"Ethical complexity of medical treatment affordability and clinical trial diversity in heart failure","volume":"17","author":"Rao BR","year":"2024","unstructured":"Rao BR, Dickert NW, Morris AA. Ethical complexity of medical treatment affordability and clinical trial diversity in heart failure. Circ Cardiovasc Qual Outcomes. 2024, 17:e010227. 10.1161\/CIRCOUTCOMES.123.010227","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350430-emerging-therapeutic-strategies-for-heart-failure-a-comprehensive-review-of-novel-pharmacological-and-molecular-targets","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T20:14:24Z","timestamp":1743538464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350430-emerging-therapeutic-strategies-for-heart-failure-a-comprehensive-review-of-novel-pharmacological-and-molecular-targets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.81573","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}